Targets › OPA1
3 programs from 3 companies in 5 trials: 2 Phase 1, 1 Phase 2, 1 Phase 4, 1 Phase 3; Ophthalmology, Other, Metabolic and endocrine; next expected readout Aug 2027.
Dynamin-related GTPase that is essential for normal mitochondrial morphology by mediating fusion of the mitochondrial inner membranes, regulating cristae morphology and maintaining respiratory chain function. Exists in two forms: the transmembrane, long form (Dynamin-like GTPase OPA1, long form; L-OPA1), which is tethered to the inner mitochondrial membrane, and the short soluble form (Dynamin-like GTPase OPA1,…. (UniProt, O60313)
Open in Phaseline: the race on OPA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Stealth BioTherapeutics | Elamipretide OPA1-targeted peptide; mitochondrial function enhancer | OPA1 | Phase 4 | Barth Syndrome; Age Related Macular Degeneration (ARMD) | Aug 2027 |
| David Marcinek | Elamipretide Mitochondrial targeting peptide; promotes optimal cristae remodeling and mitochondrial fun | OPA1 | Phase 2 | Aging, Healthy | – |
| PYC Therapeutics | PYC-001 Peptide-phosphorodiamidate morpholino oligonucleotide (PMO) targeting OPA1 | OPA1 | Phase 1 | OPA1 Gene Mutation | Oct 2029 |
OPA1 Gene Mutation (2) Aging, Healthy (1) Barth Syndrome (1) Age Related Macular Degeneration (ARMD) (1)
protein or peptide (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.